Polymorphic Effects of Cytochrome P450 3A5 on Pharmacokinetics of Maraviroc and Its Metabolites

Trial Profile

Polymorphic Effects of Cytochrome P450 3A5 on Pharmacokinetics of Maraviroc and Its Metabolites

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Oct 2015

At a glance

  • Drugs Maraviroc (Primary)
  • Indications HIV-1 infections; Rheumatoid arthritis
  • Focus Pharmacokinetics
  • Most Recent Events

    • 05 Apr 2015 Status changed from active, no longer recruiting to completed according to ClinicalTrials.gov record as reported by ClinicalTrials.gov record.
    • 14 Jan 2014 Status changed from recruiting to active, no longer recruiting according to ClinicalTrials.gov record.
    • 25 Nov 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top